Cargando…
Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study
The aim of this study is to determine the effect of repeated vaccinations on neutralizing SARS-CoV-2 IgG antibody titers, evaluate risk factors for immunological non-response, and to report breakthrough infections in chronic hemodialysis patients. Methods: A prospective, multi-center cohort study in...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181211/ https://www.ncbi.nlm.nih.gov/pubmed/35683580 http://dx.doi.org/10.3390/jcm11113187 |
_version_ | 1784723713129709568 |
---|---|
author | Tillmann, Frank-Peter Figiel, Lars Ricken, Johannes Still, Hermann Korte, Christoph Plaßmann, Grete Harth, Ana Jörres, Achim von Landenberg, Philipp |
author_facet | Tillmann, Frank-Peter Figiel, Lars Ricken, Johannes Still, Hermann Korte, Christoph Plaßmann, Grete Harth, Ana Jörres, Achim von Landenberg, Philipp |
author_sort | Tillmann, Frank-Peter |
collection | PubMed |
description | The aim of this study is to determine the effect of repeated vaccinations on neutralizing SARS-CoV-2 IgG antibody titers, evaluate risk factors for immunological non-response, and to report breakthrough infections in chronic hemodialysis patients. Methods: A prospective, multi-center cohort study in 163 chronic hemodialysis patients was conducted. Antibody titers were measured three months after second, third, and fourth (10 pts) booster vaccinations. SARS-CoV-2 neutralizing antibody titers in BAU/mL and % inhibition were divided into three categories (<216, 216–433, >433 and <33, 33–66, and >66%). Somers’s test, paired t-test, and univariable and multivariable logistic regression analysis were applied to evaluate differences in antibody levels and search for risk factors for vaccination failure defined as neutralizing titers <50% and/or need for repeated booster vaccinations. Furthermore, we report on a case series to describe characteristics of patients after four vaccinations (n = 10) and breakthrough infections (n = 20). Results: Third dose boosters resulted in higher proportions of patients with neutralizing antibody levels >66% as compared to after the second dose (64.7% after second dose vs. 88.9% after third dose, p = 0.003), as well as in a respective increase in neutralizing titer levels in % from 68 ± 33% to 89 ± 24 (p < 0.001). The proportion of patients with IgG-titers below 216 BAU/mL decreased from 38.6 to 10.5% (p ≤ 0.001). Age (p = 0.004, OR 1.066, 95% CI 1.020–1.114) and presence of immunosuppressive medications (p = 0.002, OR 8.267, 95% CI 2.206–30.975) were identified as major risk factors for vaccination failure. Repeated booster vaccinations ≥4 times were effective in 8 out of 10 former low-responders (80%) without any side effects or safety concerns. Breakthrough infections showed a clinically mild course but were associated with prolonged viral shedding on PCR-testing ranging 7–29 (mean 13) days. Conclusions: Third and fourth mRNA-based booster vaccinations resulted in higher and longer lasting SARS-CoV-2 antibody levels as compared to after two dosages. The presence of immunosuppressive medication and repeat vaccinations are major potentially modifiable measures to increase antibody levels in non-or low-responders. Breakthrough infections with SARS-CoV-2 Omicron were associated with prolonged viral shedding but clinically mild disease courses. |
format | Online Article Text |
id | pubmed-9181211 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91812112022-06-10 Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study Tillmann, Frank-Peter Figiel, Lars Ricken, Johannes Still, Hermann Korte, Christoph Plaßmann, Grete Harth, Ana Jörres, Achim von Landenberg, Philipp J Clin Med Article The aim of this study is to determine the effect of repeated vaccinations on neutralizing SARS-CoV-2 IgG antibody titers, evaluate risk factors for immunological non-response, and to report breakthrough infections in chronic hemodialysis patients. Methods: A prospective, multi-center cohort study in 163 chronic hemodialysis patients was conducted. Antibody titers were measured three months after second, third, and fourth (10 pts) booster vaccinations. SARS-CoV-2 neutralizing antibody titers in BAU/mL and % inhibition were divided into three categories (<216, 216–433, >433 and <33, 33–66, and >66%). Somers’s test, paired t-test, and univariable and multivariable logistic regression analysis were applied to evaluate differences in antibody levels and search for risk factors for vaccination failure defined as neutralizing titers <50% and/or need for repeated booster vaccinations. Furthermore, we report on a case series to describe characteristics of patients after four vaccinations (n = 10) and breakthrough infections (n = 20). Results: Third dose boosters resulted in higher proportions of patients with neutralizing antibody levels >66% as compared to after the second dose (64.7% after second dose vs. 88.9% after third dose, p = 0.003), as well as in a respective increase in neutralizing titer levels in % from 68 ± 33% to 89 ± 24 (p < 0.001). The proportion of patients with IgG-titers below 216 BAU/mL decreased from 38.6 to 10.5% (p ≤ 0.001). Age (p = 0.004, OR 1.066, 95% CI 1.020–1.114) and presence of immunosuppressive medications (p = 0.002, OR 8.267, 95% CI 2.206–30.975) were identified as major risk factors for vaccination failure. Repeated booster vaccinations ≥4 times were effective in 8 out of 10 former low-responders (80%) without any side effects or safety concerns. Breakthrough infections showed a clinically mild course but were associated with prolonged viral shedding on PCR-testing ranging 7–29 (mean 13) days. Conclusions: Third and fourth mRNA-based booster vaccinations resulted in higher and longer lasting SARS-CoV-2 antibody levels as compared to after two dosages. The presence of immunosuppressive medication and repeat vaccinations are major potentially modifiable measures to increase antibody levels in non-or low-responders. Breakthrough infections with SARS-CoV-2 Omicron were associated with prolonged viral shedding but clinically mild disease courses. MDPI 2022-06-02 /pmc/articles/PMC9181211/ /pubmed/35683580 http://dx.doi.org/10.3390/jcm11113187 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tillmann, Frank-Peter Figiel, Lars Ricken, Johannes Still, Hermann Korte, Christoph Plaßmann, Grete Harth, Ana Jörres, Achim von Landenberg, Philipp Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study |
title | Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study |
title_full | Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study |
title_fullStr | Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study |
title_full_unstemmed | Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study |
title_short | Effect of Third and Fourth mRNA-Based Booster Vaccinations on SARS-CoV-2 Neutralizing Antibody Titer Formation, Risk Factors for Non-Response, and Outcome after SARS-CoV-2 Omicron Breakthrough Infections in Patients on Chronic Hemodialysis: A Prospective Multicenter Cohort Study |
title_sort | effect of third and fourth mrna-based booster vaccinations on sars-cov-2 neutralizing antibody titer formation, risk factors for non-response, and outcome after sars-cov-2 omicron breakthrough infections in patients on chronic hemodialysis: a prospective multicenter cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181211/ https://www.ncbi.nlm.nih.gov/pubmed/35683580 http://dx.doi.org/10.3390/jcm11113187 |
work_keys_str_mv | AT tillmannfrankpeter effectofthirdandfourthmrnabasedboostervaccinationsonsarscov2neutralizingantibodytiterformationriskfactorsfornonresponseandoutcomeaftersarscov2omicronbreakthroughinfectionsinpatientsonchronichemodialysisaprospectivemulticentercohortstudy AT figiellars effectofthirdandfourthmrnabasedboostervaccinationsonsarscov2neutralizingantibodytiterformationriskfactorsfornonresponseandoutcomeaftersarscov2omicronbreakthroughinfectionsinpatientsonchronichemodialysisaprospectivemulticentercohortstudy AT rickenjohannes effectofthirdandfourthmrnabasedboostervaccinationsonsarscov2neutralizingantibodytiterformationriskfactorsfornonresponseandoutcomeaftersarscov2omicronbreakthroughinfectionsinpatientsonchronichemodialysisaprospectivemulticentercohortstudy AT stillhermann effectofthirdandfourthmrnabasedboostervaccinationsonsarscov2neutralizingantibodytiterformationriskfactorsfornonresponseandoutcomeaftersarscov2omicronbreakthroughinfectionsinpatientsonchronichemodialysisaprospectivemulticentercohortstudy AT kortechristoph effectofthirdandfourthmrnabasedboostervaccinationsonsarscov2neutralizingantibodytiterformationriskfactorsfornonresponseandoutcomeaftersarscov2omicronbreakthroughinfectionsinpatientsonchronichemodialysisaprospectivemulticentercohortstudy AT plaßmanngrete effectofthirdandfourthmrnabasedboostervaccinationsonsarscov2neutralizingantibodytiterformationriskfactorsfornonresponseandoutcomeaftersarscov2omicronbreakthroughinfectionsinpatientsonchronichemodialysisaprospectivemulticentercohortstudy AT harthana effectofthirdandfourthmrnabasedboostervaccinationsonsarscov2neutralizingantibodytiterformationriskfactorsfornonresponseandoutcomeaftersarscov2omicronbreakthroughinfectionsinpatientsonchronichemodialysisaprospectivemulticentercohortstudy AT jorresachim effectofthirdandfourthmrnabasedboostervaccinationsonsarscov2neutralizingantibodytiterformationriskfactorsfornonresponseandoutcomeaftersarscov2omicronbreakthroughinfectionsinpatientsonchronichemodialysisaprospectivemulticentercohortstudy AT vonlandenbergphilipp effectofthirdandfourthmrnabasedboostervaccinationsonsarscov2neutralizingantibodytiterformationriskfactorsfornonresponseandoutcomeaftersarscov2omicronbreakthroughinfectionsinpatientsonchronichemodialysisaprospectivemulticentercohortstudy |